Diagnosis and pathophysiology of migraine

Expert Review of Neurotherapeutics

Volumn 4, Issue 3, 2004, Pages 383-390

  Ward, Thomas N ^a   Levin, Morris ^a  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

Dopamine; Familial hemiplegic; International Headache Society; Migraine; Neuroimaging; Pathophysiology; S hydroxytryptamine; Serotonin; Trigeminovascular; Triptans

Indexed keywords

ALMOTRIPTAN; BOTULINUM TOXIN A; CAFERGOT; ELETRIPTAN; ERGOTAMINE; FROVATRIPTAN; NARATRIPTAN; RIZATRIPTAN; SEROTONIN AGONIST; SUMATRIPTAN; SUMATRIPTAN SUCCINATE; ZOLMITRIPTAN;

AWARENESS; DIAGNOSTIC ACCURACY; HEADACHE; HEALTH CARE; HUMAN; MIGRAINE; PATHOPHYSIOLOGY; REVIEW;

HUMANS; MIGRAINE DISORDERS; TRYPTAMINES;

EID: 2342605498     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.4.3.383     Document Type: Review

References (54)

1. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the united states. Data from the American Migraine Study II. Headache 41, 646-657 (2001).
2. Hu HX, Markson LE, Lipton RB, Stewart WF, Berger ML. Burden of migraine in the United States: disability and economic costs. Arch. Intern. Med. 159(8), 813-818 (1999).
3. Stewart WF, Ricci JA, Chee E, Morganstein D, Lipton R. Lost productive time and cost due to common pain conditions in the US workforce. JAMA 290, 2443-2454 (2003).
4. Graham JR, Wolff HG. Mechanisms of migraine headache and action of ergotamine tartrate. Arch. Neurol. Psych. 39, 737-763 (1938).
5. Goadsby PJ, Lipton, RB, Ferrari MD. Migraine: current understanding and management. N. Engl. J. Med. 346, 257-270 (2002). Excellent review of the current understanding of migraine and how therapy relates to pathophysiology.
6. Ad Hoc Committee on Classification of Headache. Classification of headache. JAMA 179, 717-718 (1962).
7. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgia and facial pain. Cephalalgia 8(Suppl. 7), 1-96 (1988).
8. Smith R, Hasse LA, Ritchey PN, Cassedy AE, Rudawsky DJ. Extent of migraine and migrainous headache NOS in family practice. Cephalalgia 21, 291-292 (2001).
9. Lipton RB, Stewart WF, Simon D. Medical consultation for migraine: results from the American Migraine Study. Headache 38, 87-96 (1998).
10. Tepper SJ, Dahlöf C, Dowson A, Newman L. prevalence and diagnosis of migraine in patients consulting their physician with a complaint of headache: data from The Landmark Study. (2004) (In Press). Useful data about accuracy of migraine diagnosis in primary care offices worldwide.
11. Kaniecki RG. Migraine and tension-type headache: an assessment of challenges in diagnosis. Neurology 58(Suppl. 6), S15-S20 (2002).
12. Cady RK, Schreiber CP. Sinus headache or migraine? Considerations in making a differential diagnosis. Neurology 58(Suppl. 6), S10-S14 (2002).
13. Lipton RB, Dodick D, Sadovsky R, Kolodner K, Endicott J, Hettiatachchi J, Harrison W. A self-administered screener for migraine in primary care. The ID Migraine™ validation study. Neurology 61, 375-382 (2003).
14. Lipton RB, Stewart WF, Stone AM, Lainez MJ, Sawyer JP. Stratified care vs. step care strategies for migraine. The Disabilty in Strategies of Care (DISC) study, a randomized trial. JAMA 284, 2499-2505 (2000).
15. Lipton RB, Stewart WF, Sawyer J, Edmeads JG. Clinical utility of an instrument assessing migraine disability: the Migraine Disability Assessment (MIDAS) questionnaire. Headache 41(9), 854-861 (2001).
16. Silberstein SD, Lipton RB, Goadsby PJ. Headache in Clinical Practice. Second Edition. Martin Dunitz, London, UK (2002). Outstanding textbook which thoroughly reviews the topic of headache.
17. Barbanti P, Fabbrini G, Pesare M, Vanacore N, Cerbo R. Unilateral cranial autonomic symptoms in migraine. Cephalalgia 22(4), 256-259 (2002).
18. Peroutka SJ. The pharmacology of current antimigraine drugs. Headache 30(Suppl. 1), 5-11 (1990).
19. Curran DA, Hintterberger H, Lance JW. Total plasma serotonin, 5-hydroxyindoleacetic acid and p-hydroxy-m-methoxymandelic acid excretion in normal and migrainous subjects. Brain 88, 997-1010 (1965).
20. Kimball RW, Friedman AP, Vallejo E. Effect of serotonin in migraine patients. Neurology 10, 107-111 (1960).
21. Humphrey PPA, Feniuk W, Perren MJ. Antimigraine drugs in development: advances in serotonin receptor pharmacology. Headache 30(Suppl. 1), 12-16 (1990).
22. Joutel A, Bausser MG, Biousee V. A gene for familial hemiplegic migraine maps to chromosome 19. Nature Genet. 5, 40-45 (1993).
23. May A, Ophoff RA, Terwindt GM et al. Familial hemiplegic migraine locus on chromosome 19p13 is involved in the common forms of migraine with and without aura. Hum. Genet. 96, 604-608 (1995). Key article in understanding underlying genetic/pathophysiologic abnormalities in migraine.
24. 2+ channel gene CACNLA4. Cell Tiss. Res. 87, 543-552 (1996).
25. Ramadan NM, Halvorson H, VandeLinde A, Levine SR, Helpen JA, Welch KMA. Low brain magnesium in migraine. Headache 29, 416-419 (1989).
26. Welch KM, D'Andrea G, Tepley N, Barkley G, Ramadan NM. The concept of migraine as a state of central neuronal hyperexcibility. Neurologic Clinics 8(4), 817-828 (1990).
27. + pump α2 subunit associated with familial hemiplegic migraine type 2*. Nature Genet. 33(2), 192-196 (2003)
28. Peroutka SJ, Wilhoit T, Jones K. Clinical susceptibility to migraine with aura is modified by dopamine D2 receptor (DRD2) Ncol alleles. Eurology 49, 201-206 (1997).
29. Markowitz S, Saito K, Moskowitz MA. Neurogenically mediated plasma extravasation in dura mater: effect of ergot alkaloids. A possible mechanism of action in vascular headache. Cephalalgia 8(2), 83-91 (1988).
30. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann. Neurol. 28, 183-187 (1990).
31. Roon KI, Olesen J, Diener HC et al. No acute antimigraine efficacy of CP-122,288, a highly potent inhibitor of neurogenic inflammation: results of two randomized double-blind, placebo-controlled clinical trials. Ann. Neurol. 47, 238-241 (2000).
32. Doods H, Hallermayer G, Wu D et al. Pharmacologic profile of BIBN-4096BS, the first selective small molecule CGRP antagonist. Br. J. Pharmacol. 129, 420-423 (2000).
33. Hoskins KL, Kaube H, Goadsby PJ. Central activation of the trigeminovascular pathway in the cat is inhibited by dihydroergotamine: a c-fos and electrophysiologic study. Brain 119, 249-256 (1996).
34. Mendell LM. Physiologic properties of unmyelinated fibre projection to the spinal cord. Exp. Neurol. 16, 316-332 (1966).
35. Woolf, CJ. Central sensitization: implications for the pathogenesis of headache. In: Towards Migraine 2000. Rose FC (Ed.). Elsevier, London, UK, 173-181 (1996).
36. Burstein R, Cutrer FM, Yarnitsky D. The development of cutaneous allodynia during a migraine attack: clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain 123, 1703-1709 (2000).
37. Burstein R, Collins B, Bajwa Z, Jukubowski M. Triptan therapy can abort migraine attacks if given before the establishment or in the absence of cutaneous allodynia and central sensitization: clinical and preclinical evidence. Headache 42(5), 390-391 (2002).
38. Burstein R, Jakubowski M. Analgesic triptan action in an animal model of intracranial pain: a race against the development of central sensitization. Ann. Neurol. 55 (1), 27-36(2004).
39. Woolf CJ. Somatic pain: pathogenesis and prevention. Br. J. Anaesth. 75, 169-176 (1995).
40. Rasmussen BK, Olesen J. Migraine with aura and migraine without aura: an epidemiologic study. Cephalalgia 12, 221-228 (1992).
41. Olesen J, Larsen B, Lauritzen M. Focal hyperemia followed by spreading oligemia and impaired activation of RCBF in classic migraine. Ann. Neurol. 9, 344-352 (1981).
42. Lashley KS. Patterns of cerebral integration indicated by the scotomas of migraine. Arch. Neurol. 46, 331-339 (1941).
43. Leao AAP. Spreading depression of activity in cerebral cortex. J. Neurophysiol. 7, 359-390 (1944).
44. Woods RP, Iacoboni M, Mazziotta JC. Bilateral spreading cerebral hypoperfusion during spontaneous migraine headaches. N Engl. J Med. 331, 1689-1692 (1994).
45. Hadjikhani N, Sanchez Del Rio M, Wu O et al. Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc. Natl Acad Sci 98(8), 4687-4692 (2001).
46. Bolay H, Reuter U, Dunn AK, Huang Z, Boas DA, Moskowitz MA. Intrinsic brain activity triggers trigeminal afferents in a migraine model. Nature Med 8(2), 136-142 (2002). Important article explaining the dynamics of migraine pathophysiology.
47. Iadecola C. From CSD to headache: a long and winding road. Nature Med. 8(2), 110-112 (2002).
48. Weiller C, May A, Limmroth V et al. Brainstem activation in spontaneous human migraine attacks. Nature Med. 1(7), 658-660 (1995).
49. Raskin NH, Hosobuchi Y, Lamb S. Headache may arise from perturbation of brain. Headache 27, 416-420 (1987).
50. Ward TN, Levin M. Headache caused by a spinal cord stimulator in the upper cervical spine. Headache 40, 689-691 (2000).
51. Welch KM, Nagesh V, Aurora SK, Gelman N. Periaqueductal gray matter dysfunction in migraine: cause or the burden of illness? Headache 41(7), 629-637 (2001). Important article suggesting possible brain damage/dysfunction in patients with chronic headaches.
52. Humphrey PP, Bland-Ward PA, Carruthers AM et al. Inhibition of trigeminal nociceptive afferents by adenosine A1 receptor activation: a novel approach towards the design of new antimigraine compounds. Cephalalgia 21, 268-269 (2001).
53. Olesen J, Diener HC, Husstedt IW et al. Calcitonin Gene-related Peptide Receptor Antagonist BIBN 4096 BS for the Acute Treatment of Migraine. N. Engl. J. Med. 350(11), 1104-1110 (2004)
54. Silberstein SD, Mathew N, Saper J, Jenkins S. Botulinum toxin type A as a migraine preventative treatment. Headache 40, 445-450 (2000).